P&G Hygiene & Health Care Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹28,047 Cr
- Book Value
- ₹232
- Stock P/E
- 35.5
- Dividend Yield
- 2.66%
- ROE
- 114.9%
- ROCE
- 157.5%
- PEG Ratio
- 2.44
- EV/EBITDA
- 24.6
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
P&G Hygiene & Health Care share price today
P&G Hygiene & Health Care (NSE: PGHH) owns two categories outright: Whisper defines feminine hygiene in India, Vicks defines cold-and-cough care — brands so synonymous with their categories that the product name is the category name in most households. The capital efficiency is the highest among India’s FMCG listings, and it isn’t close: 157.5% ROCE, 114.9% ROE, zero debt, with a 2.66% dividend shipping the surplus out.
Growth is the honest constraint — 7.4% five-year sales CAGR reflects category maturity in urban markets — while the penetration story (feminine hygiene usage across Bharat remains far below saturation) grinds forward. At 35.5×, our universe tags it wait: perfection priced as perfection.
Two category kings, one tiny balance sheet
Whisper’s moat compounds through taboo-breaking marketing that competitors must free-ride or match, retail depth into kirana counters, and product laddering from value to premium. Vicks is winter’s annuity — a century-old brand whose habit formation no challenger has dented. Both need almost no capital: manufacturing is compact, brands are amortised history, and P&G’s shared distribution muscle carries the rest — hence return ratios that read like typos.
Watch-items: penetration-led volume growth (the whole thesis), competitive intensity in feminine hygiene’s value tier, parent royalty rates (periodically raised, periodically contested), and rural consumption cycles.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹28,047 Cr |
| P/E (TTM) | 35.5 |
| EV/EBITDA | 24.6 |
| Operating margin | 25.3% |
| ROE / ROCE | 114.9% / 157.5% |
| Debt to equity | 0.00 |
| Sales CAGR (5y) | 7.4% |
| Profit CAGR (5y) | 14.5% |
| Promoter holding | 70.6% |
| EPS (TTM) | ₹243.6 |
P&G Hygiene share price target 2026 to 2030
EPS base ₹243.6 (TTM). Bear: category maturity wins — 6% growth, multiple at 26×. Base: penetration grinds, margins mix up — 11% growth at 32×. Bull: rural adoption accelerates the curve — 15% growth at 40×.
| Year | Bear (26×, +6%) | Base (32×, +11%) | Bull (40×, +15%) |
|---|---|---|---|
| 2026 | ₹6,715 | ₹8,655 | ₹11,205 |
| 2027 | ₹7,115 | ₹9,605 | ₹12,885 |
| 2028 | ₹7,545 | ₹10,660 | ₹14,820 |
| 2029 | ₹7,995 | ₹11,835 | ₹17,040 |
| 2030 | ₹8,475 | ₹13,135 | ₹19,600 |
From ₹8,640, the base case is ≈ +52% over four and a half years plus the 2.66% yield; the bear is −2%. Category kings with 157% ROCE don’t offer drama — they offer arithmetic. The range below improves the arithmetic.
Reasons to own PGHH (at the right price)
- 157% ROCE — India’s capital-efficiency champion among consumer listings.
- Whisper and Vicks are category-defining brands with generational habit moats.
- A 2.66% yield from a business that cannot spend its own cash.
- Feminine-hygiene penetration is a decade-length volume runway.
- Zero debt, MNC governance, and pricing power inflation keeps validating.
The risks: single-digit sales growth is the structural ceiling until penetration inflects, value-tier competition presses Whisper’s entry price points, and royalty escalations recur as a minority-shareholder theme.
Should you buy at the current price?
The live buy range below is for members — the kings, bought on their quiet days.
FAQ
What is the PGHH share price target for 2030? Base case ≈ ₹13,135 (32× on 11% compounded growth), bear ≈ ₹8,475, bull ≈ ₹19,600. Arithmetic above.
How is 157% ROCE possible? Almost no capital employed: brands built decades ago, compact manufacturing, distribution shared with the P&G group. Large profits over a tiny capital base produce extraordinary ratios.
Where does growth come from if categories are mature? Penetration (feminine hygiene usage outside metros is still far from universal), premiumisation (product laddering), and pricing — a grind, not a sprint, which the multiple must respect.
When are PGHH’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.